Renaissance Technologies
RNTX

Renaissance Technologies’s Rein Therapeutics RNTX Stock Holding History

Renaissance Technologies’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.8K Sell
19,000
-5,500
-22% -$6.66K ﹤0.01% 3095
2026
Q1 		$31.9K Buy
24,500
+1,800
+8% +$2.23K ﹤0.01% 3138
2025
Q4 		$26.3K Buy
22,700
+4,402
+24% +$6.07K ﹤0.01% 3130
2025
Q3 		$21K Buy
+18,298
New +$23.2K ﹤0.01% 3421
2024
Q4 		– Sell
-13,164
Closed -$46.6K – 3981
2024
Q3 		$46.6K Sell
13,164
-11,700
-47% -$31.3K ﹤0.01% 3352
2024
Q2 		$68.9K Sell
24,864
-20,200
-45% -$83K ﹤0.01% 3245
2024
Q1 		$299K Buy
45,064
+17,045
+61% +$81.6K ﹤0.01% 3091
2023
Q4 		$85K Buy
28,019
+9,055
+48% +$17.7K ﹤0.01% 3345
2023
Q3 		$29K Buy
18,964
+3,100
+20% +$5.26K ﹤0.01% 3478
2023
Q2 		$28K Buy
15,864
+3,200
+25% +$4.93K ﹤0.01% 3720
2023
Q1 		$16K Buy
12,664
+2,100
+20% +$4.5K ﹤0.01% 3851
2022
Q4 		$25K Buy
10,564
+1,029
+11% +$3.46K ﹤0.01% 3931
2022
Q3 		$39K Buy
9,535
+3,775
+66% +$15.9K ﹤0.01% 3813
2022
Q2 		$30K Buy
5,760
+2,835
+97% +$26K ﹤0.01% 4080
2022
Q1 		$30K Sell
2,925
-20,597
-88% -$186K ﹤0.01% 3971
2021
Q4 		$265K Sell
23,522
-13,214
-36% -$204K ﹤0.01% 3398
2021
Q3 		$749K Sell
36,736
-14,820
-29% -$325K ﹤0.01% 2705
2021
Q2 		$1.29M Sell
51,556
-10,969
-18% -$274K ﹤0.01% 2532
2021
Q1 		$1.79M Buy
62,525
+30,806
+97% +$1.06M ﹤0.01% 2295
2020
Q4 		$660K Sell
31,719
-28,502
-47% -$712K ﹤0.01% 2705
2020
Q3 		$1.55M Sell
60,221
-8,973
-13% -$211K ﹤0.01% 2270
2020
Q2 		$1.63M Buy
69,194
+45,335
+190% +$739K ﹤0.01% 2288
2020
Q1 		$158K Sell
23,859
-695
-3% -$8.37K ﹤0.01% 3143
2019
Q4 		$281K Buy
24,554
+7,542
+44% +$74.4K ﹤0.01% 3088
2019
Q3 		$228K Buy
17,012
+7,185
+73% +$99.4K ﹤0.01% 3111
2019
Q2 		$142K Buy
9,827
+2,661
+37% +$69.8K ﹤0.01% 3357
2019
Q1 		$279K Sell
7,166
-2,883
-29% -$89.8K ﹤0.01% 3115
2018
Q4 		$169K Buy
10,049
+7,562
+304% +$304K ﹤0.01% 3163
2018
Q3 		$137K Buy
+2,487
New +$167K ﹤0.01% 3211

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Renaissance Technologies's RNTX Position: Q2 2026 in Review

Renaissance Technologies reduced its Rein Therapeutics (RNTX) stake by 22% in Q2 2026, selling an estimated $6.66K and leaving 19,000 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3095.

Renaissance Technologies first reported a position in RNTX in Q3 2018 and has held it in 29 quarters since. The position peaked at $1.79M in Q1 2021. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Renaissance Technologies held 19,000 shares of Rein Therapeutics worth $19.8K as of Q2 2026.
  • Renaissance Technologies sold 5,500 Rein Therapeutics shares in Q2 2026, an estimated $6.66K.
  • Rein Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #3095 holding.
  • Renaissance Technologies first reported a position in Rein Therapeutics in Q3 2018 and has held it in 29 quarters since.
  • Renaissance Technologies's Rein Therapeutics position peaked at $1.79M in Q1 2021.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.